Insmed (INSM) Stock Forecast & Price Target

Compare

1,061 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

18 Buy

1 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$217.71

▲(35.22% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $217.71 with a high forecast of $263.00 and a low forecast of $166.00. The average price target represents a 35.22% change from the last price of $161.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"70":"$70","167":"$167","264":"$264","118.5":"$118.5","215.5":"$215.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$263.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":217.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$217.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$166.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[70,118.5,167,215.5,264],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.98,162.36615384615385,170.75230769230768,179.13846153846154,187.52461538461537,195.91076923076923,204.29692307692306,212.68307692307692,221.06923076923078,229.45538461538462,237.84153846153845,246.2276923076923,254.61384615384617,{"y":263,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.98,158.88230769230768,163.78461538461536,168.68692307692308,173.58923076923077,178.49153846153845,183.39384615384614,188.29615384615386,193.19846153846154,198.10076923076923,203.00307692307692,207.9053846153846,212.80769230769232,{"y":217.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,153.98,154.90461538461537,155.82923076923075,156.75384615384615,157.67846153846153,158.6030769230769,159.5276923076923,160.4523076923077,161.37692307692308,162.30153846153846,163.22615384615384,164.15076923076924,165.07538461538462,{"y":166,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.28,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":189.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":211.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$263.00

Average Price Target$217.71

Lowest Price Target$166.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Brill

Truist Financial

Buy

―

Reiterated

02/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Insmed (NASDAQ: INSM)

Maxwell Skor

Morgan Stanley

$162→$166

Hold

3.11%

Upside

Reiterated

02/20/26

Insmed: Early Brinsupri Momentum but Policy Uncertainty and 2026 Pipeline Catalysts Justify Hold Rating

Tiago Fauth

Wells Fargo

$234→$208

Buy

29.19%

Upside

Reiterated

02/20/26

Insmed price target lowered to $208 from $234 at Wells FargoInsmed price target lowered to $208 from $234 at Wells Fargo

Adam Walsh

Roth MKM

$212

Buy

31.68%

Upside

Reiterated

02/20/26

Analysts' Top Healthcare Picks: Insmed (INSM), Irhythm Technologies (IRTC)

Ritu Baral

TD Cowen

$241

Buy

49.69%

Upside

Reiterated

02/19/26

Brinsupri’s Breakout Growth, Robust Balance Sheet, and Upcoming Clinical Catalysts Underpin Buy Rating

Graig Suvannavejh

Mizuho Securities

$212→$211

Buy

31.06%

Upside

Reiterated

02/19/26

Insmed price target lowered to $211 from $212 at MizuhoInsmed price target lowered to $211 from $212 at Mizuho

Leonid Timashev

RBC Capital

$200

Buy

24.22%

Upside

Reiterated

02/19/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Jason Zemansky

Bank of America Securities

$209→$211

Buy

31.06%

Upside

Reiterated

02/19/26

Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM)

Stephen Willey

Stifel Nicolaus

$212→$205

Buy

27.33%

Upside

Reiterated

02/19/26

Analysts Offer Insights on Healthcare Companies: Talkspace (NASDAQ: TALK) and Insmed (NASDAQ: INSM)

Matt Phipps

William Blair

Buy

―

Reiterated

02/19/26

Insmed: Strengthening Commercial Profile and Favorable Pricing Support Buy Rating and Multi‑Year Growth Outlook

Andrea Newkirk

Goldman Sachs

$225→$230

Buy

42.86%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Zimmer Biomet Holdings (NYSE: ZBH) and Roivant Sciences (NASDAQ: ROIV)

Gavin Clark-Gartner

Evercore ISI

$233→$208

Buy

29.19%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Oncolytics Biotech (NASDAQ: ONCY) and Imunon (NASDAQ: IMNN)

Eliana Merle

Barclays

$231

Buy

43.48%

Upside

Initiated

01/27/26

Insmed initiated with an Overweight at BarclaysInsmed initiated with an Overweight at Barclays

Ashwani Verma

UBS

$223→$215

Buy

33.54%

Upside

Reiterated

01/05/26

UBS Remains a Buy on Insmed (INSM)

Andrew Fein

H.C. Wainwright

$240→$230

Buy

42.86%

Upside

Reiterated

12/18/25

Insmed: Managing CRSsNP Setback While Leveraging a Diversified, Innovation-Rich Respiratory Pipeline to Support Buy Rating and $230 Target

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Brill

Truist Financial

Buy

―

Reiterated

02/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Insmed (NASDAQ: INSM)

Maxwell Skor

Morgan Stanley

$162→$166

Hold

3.11%

Upside

Reiterated

02/20/26

Insmed: Early Brinsupri Momentum but Policy Uncertainty and 2026 Pipeline Catalysts Justify Hold Rating

Tiago Fauth

Wells Fargo

$234→$208

Buy

29.19%

Upside

Reiterated

02/20/26

Insmed price target lowered to $208 from $234 at Wells FargoInsmed price target lowered to $208 from $234 at Wells Fargo

Adam Walsh

Roth MKM

$212

Buy

31.68%

Upside

Reiterated

02/20/26

Analysts' Top Healthcare Picks: Insmed (INSM), Irhythm Technologies (IRTC)

Ritu Baral

TD Cowen

$241

Buy

49.69%

Upside

Reiterated

02/19/26

Brinsupri’s Breakout Growth, Robust Balance Sheet, and Upcoming Clinical Catalysts Underpin Buy Rating

Graig Suvannavejh

Mizuho Securities

$212→$211

Buy

31.06%

Upside

Reiterated

02/19/26

Insmed price target lowered to $211 from $212 at MizuhoInsmed price target lowered to $211 from $212 at Mizuho

Leonid Timashev

RBC Capital

$200

Buy

24.22%

Upside

Reiterated

02/19/26

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

Jason Zemansky

Bank of America Securities

$209→$211

Buy

31.06%

Upside

Reiterated

02/19/26

Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM)

Stephen Willey

Stifel Nicolaus

$212→$205

Buy

27.33%

Upside

Reiterated

02/19/26

Analysts Offer Insights on Healthcare Companies: Talkspace (NASDAQ: TALK) and Insmed (NASDAQ: INSM)

Matt Phipps

William Blair

Buy

―

Reiterated

02/19/26

Insmed: Strengthening Commercial Profile and Favorable Pricing Support Buy Rating and Multi‑Year Growth Outlook

Andrea Newkirk

Goldman Sachs

$225→$230

Buy

42.86%

Upside

Reiterated

02/11/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Insmed (NASDAQ: INSM), Zimmer Biomet Holdings (NYSE: ZBH) and Roivant Sciences (NASDAQ: ROIV)

Gavin Clark-Gartner

Evercore ISI

$233→$208

Buy

29.19%

Upside

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Oncolytics Biotech (NASDAQ: ONCY) and Imunon (NASDAQ: IMNN)

Eliana Merle

Barclays

$231

Buy

43.48%

Upside

Initiated

01/27/26

Insmed initiated with an Overweight at BarclaysInsmed initiated with an Overweight at Barclays

Ashwani Verma

UBS

$223→$215

Buy

33.54%

Upside

Reiterated

01/05/26

UBS Remains a Buy on Insmed (INSM)

Andrew Fein

H.C. Wainwright

$240→$230

Buy

42.86%

Upside

Reiterated

12/18/25

Insmed: Managing CRSsNP Setback While Leveraging a Diversified, Innovation-Rich Respiratory Pipeline to Support Buy Rating and $230 Target

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months

xxx

Success Rate

13/17 ratings generated profit

Average Return

+26.05%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +26.05% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

20/20 ratings generated profit

Average Return

+98.05%

reiterated a buy rating 5 months ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +98.05% per trade.

2 Years

xxx

Success Rate

20/20 ratings generated profit

Average Return

+220.71%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +220.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 38 Buy Ratings, 35 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 217.71.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$0.97 with a range of -$1.96 to -$0.45. The previous quarter’s EPS was -$1.54. INSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $298.88M with a range of $245.26M to $341.04M. The previous quarter’s sales results were $263.84M. INSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year INSM has Performed in-line its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 217.71.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 35.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 18 buy ratings, 1 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 217.71. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $263.00 ,the lowest forecast is $166.00. The average price target represents 35.22% Increase from the current price of $161.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Detailed List of Analyst Forecasts